Navigation Links
Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
Date:4/17/2008

JENA, Germany, April 17 /PRNewswire/ -- Occlutech GmbH, the leading European manufacturer of cardiac occlusion devices today announced a clarification of a recent news release.

In a news release dated February 8th, 2008, Occlutech stated that it received an opinion from AIPPI the European "Association for the Protection of Intellectual Property" with regard to non infringement by Occlutech of certain European IP held by AGA Medical.

AIPPI has requested a clarification of this statement:

1) The name European International Association for the Protection of Intellectual Property was not stated correctly. The correct name is the "International Association for the Protection of Intellectual Property".

2) The opinion received by Occlutech which states that Occlutech is not infringing EP 0808138B1 and its Italian part 019020BE/2006 held by AGA Medical Corp was commissioned through the Italian National Group of AIPPI but not issued by AIPPI International itself. The opinion was issued by and in the name of three independent experts nominated by the Italian Group of AIPPI. The opinion was issued by the experts nominated by the Italian Branch of AIPPI and not by, in the name of or on behalf of AIPPI International or the Italian National Group of AIPPI.

The opinion was given without influence of Occlutech GmbH and the impartiality of the experts has subsequently been confirmed by the Italian Branch of AIPPI.

3) Such an independent opinion commissioned through AIPPI is an instrument aiming at giving the requiring party a qualified and impartial opinion. It does not represent an official opinion by AIPPI since AIPPI does not get involved in intellectual property disputes between parties on behalf or in favour of one of the parties.

Occlutech GmbH regrets that its communication was not clear with regard to the role of AIPPI in commissioning and receiving the opinion.

Occlutech GmbH develops and manufactures a wide range of occluders that are sold under the Occlutech Figulla N brand in over 40 countries in European and international markets. Clinical programs leading to regulatory approval in the US and Japan are underway.

Contact:

Robert Moszner

e-mail: robert.moszner@occlutech.com

Phone: +49-3641-67-51-20

Susanne Goransson

e-mail: info@occlutech.info

Phone: +46-704336521


'/>"/>
SOURCE Occlutech GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
2. Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions
3. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
4. Oncothyreon announces effectiveness of shelf registration statement
5. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
6. Evotecs Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective
7. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
8. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
9. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
10. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
11. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016 Should antibiotic bone cement ... products to prevent infection after standard total hip or ... at ECRI Institute have been fielding a lot lately. ... Your Bottom Line?" --> "Antibiotic ... --> While there isn,t a ...
(Date:2/8/2016)...  BioElectronics Corporation (OTC Pink: BIEL), the maker ... it is responding to a notice of an ... Exchange Commission posted on the agency website.  ... Board of BioElectronics Corporation and the Edward and ... Fuqua School of Business, Duke University.   ...
(Date:2/8/2016)... has an active R&D program for the development of ... Group has a unique research and development center in ... Bio Control products. Stockton has a ... regulatory guidelines, and is active in more than 35 counties ... Stockton,s flagship product Timorex Gold ® ...
(Date:2/5/2016)... ATCC, the premier global biological materials resource ... and life science researchers that are working to address ... CDC website . --> CDC ... a single-stranded RNA virus of the Flaviviridae family, genus ... Chikungunya Viruses. Zika virus is transmitted to humans primarily ...
Breaking Biology Technology:
(Date:2/1/2016)... Feb. 1, 2016  Today, the first day of ... plans to develop a first of its kind workplace ... IBM Watson. In the first application of ... IBM ), and Welltok will create a new ... with cognitive analytics, delivered on Welltok,s health optimization platform. ...
(Date:1/25/2016)... 25, 2016   Unisys Corporation (NYSE: UIS ) ... Kennedy (JFK) International Airport, New York City , ... imposters attempting to enter the United States ... pilot testing of the system at Dulles last ... at JFK during January 2016. --> pilot testing ...
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
Breaking Biology News(10 mins):